跳至主要内容
临床试验/NL-OMON24347
NL-OMON24347尚未招募不适用

Exploring bleeding risk and platelet function combined with multiple omics techniques in 22q11.2 deletion syndrome

one0 个研究点目标入组 60 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
one
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • In order to be eligible to participate in this study, a subject must meet all of the following criteria:
  • -16 years or older.
  • -signed informed consent.
  • Adults with 22q11.2DS
  • -molecularly confirmed 22q11.2 deletion syndrome.
  • -Mentally competent (ability to give informed consent) and aged 16 years and older or, in case the individual is mentally incompetent aged 16 years and older, consent will be given by the legally authorized representative of the subject.

排除标准

  • -The presence of any malignancy.
  • -Use of antiplatelet or anticoagulant drugs within the last two weeks prior to the study.
  • -Use of anti-inflammatory drugs within the last two weeks prior to the study.
  • - Medical history of auto-immune thrombocytopenia
  • Specific for healthy controls:
  • -A medical history of thrombocytopenia (<150.000 platelets per mL).
  • -Increased bleeding risk, defined as a diagnosed bleeding disorder.
  • -Metabolic disorder.

研究者

发起方
one

相似试验